Publications by authors named "Relinde Lieverse"

Claim this Profile
I
Improving Patient Engagement in Phase 2 Clinical Trials With a Trial-Specific Patient Decision Aid: Development and Usability Study.
Iva Halilaj, Relinde Lieverse, Cary Oberije, Lizza Hendriks, Charlotte Billiet

J Med Internet Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving shared decision making for lung cancer treatment by developing and validating an open-source web based patient decision aid for stage I-II non-small cell lung cancer.
Iva Halilaj, Anshu Ankolekar, Anouk Lenaers, Avishek Chatterjee, Cary J G Oberije, Relinde I Y Lieverse

Front Digit Health· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study.
Evert Jan Van Limbergen, Ann Hoeben, Relinde I Y Lieverse, Ruud Houben, Chantal Overhof

Int J Radiat Oncol Biol Phys· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
Veronica Olivo Pimentel, Damiënne Marcus, Alexander Ma van der Wiel, Natasja G Lieuwes, Rianne Biemans, Relinde Iy Lieverse

J Immunother Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy.
Damiënne Marcus, Relinde I Y Lieverse, Carmen Klein, Amir Abdollahi, Philippe Lambin

Cancers (Basel)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human fibronectin extra domain B as a biomarker for targeted therapy in cancer.
Relinde I Y Lieverse, Damiënne Marcus, Alexander M A van der Wiel, Evert J Van Limbergen, Jan Theys

Mol Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
Relinde I Y Lieverse, Evert J Van Limbergen, Cary J G Oberije, Esther G C Troost, Sine R Hadrup

BMC Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoxia PET Imaging with [18F]-HX4-A Promising Next-Generation Tracer.
Sebastian Sanduleanu, Alexander M A van der Wiel, Relinde I Y Lieverse, Damiënne Marcus, Abdalla Ibrahim

Cancers (Basel)· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiomics: from qualitative to quantitative imaging.
William Rogers, Sithin Thulasi Seetha, Turkey A G Refaee, Relinde I Y Lieverse, Renée W Y Granzier

Br J Radiol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphocyte-Sparing Radiotherapy: The Rationale for Protecting Lymphocyte-rich Organs When Combining Radiotherapy With Immunotherapy.
Philippe Lambin, Relinde I Y Lieverse, Franziska Eckert, Damiënne Marcus, Cary Oberije

Semin Radiat Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis